20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T11230 | ERRα antagonist-1 | ERR+/- antagonist-1,ERRa antagonist-1 | Estrogen/progestogen Receptor |
ERRα antagonist-1 (ERR+/- antagonist-1) is a high-affinity, selective antagonist of the estrogen-related receptor α (ERRα). It effectively prevents the interaction of ERRα with both Proliferator-activated Receptor γ Coac... | |||
T39078 | CXCR7 antagonist-1 | CXCR7 antagonist-1 | CXCR |
CXCR7 antagonist-1 is a specific antagonist of the binding of the SDF-1 chemokine or I-TAC to the chemokine receptor CXCR7. CXCR7 antagonist-1 prevents tumor cell proliferation and tumor formation and can be used in stud... | |||
T15785 | LPA1 receptor antagonist 1 | LPA1 R antagonist 1 | LPA Receptor |
LPA1 receptor antagonist 1(LPA1 R antagonist 1) is a selective and potent lysophosphatidic acid (LPA1) receptor antagonist (IC50 : 25 nM) for the study of idiopathic pulmonary fibrosis. | |||
T10031 | EP1-antagonist-1 | EP1-antanoist-1,EP1 antagonist 1 | Prostaglandin Receptor |
EP1-antagonist-1 (EP1 antagonist 1) is an EP1 antagonist (pKi: 7.54; pIC50: 8.5). | |||
T37792 | A2A receptor antagonist 1 | CPI-444 analog,A2A receptor antagonist 1 | Adenosine Receptor |
A2A receptor antagonist 1 (CPI-444 analog) is an antagonist of both adenosine A2A receptor and A1 receptor with Kis of 4 and 264 nM, respectively. | |||
T13216 | TSHR antagonist S37 | TSH Receptor | |
TSHR antagonist S37 is a selective and competitive antagonist of the thyrotropin receptor (TSHR). | |||
T5698 | TRPM8 antagonist 2 | TRP/TRPV Channel | |
TRPM8 antagonist 2 is a potent and selective TRPM8 antagonist with an IC50 of 0.2 nM. TRPM8 antagonist 2 is used in the research of neuropathic pain syndromes. | |||
T9709 | TRPM8 antagonist 3 | TRP/TRPV Channel | |
TRPM8 antagonist 3 is a blocker of TRPM8 (IC50 = 11 nM). | |||
T14881 | CB1 antagonist 2 | AM4113 | Cannabinoid Receptor |
CB1 antagonist 2 (AM4113) is caimabinoid 1 (CB1) antagonist which inhibits CB1 in vivo with an IC50 of 25.5 nM. | |||
T10058 | A2B receptor antagonist 1 | Adenosine Receptor | |
A2B receptor antagonist 1 (EXAMPLE 9B) is a potent A2B adenosine receptor antagonist. | |||
T10712 | CCR2 antagonist 3 | AZD-2927,AZD2927 | CCR |
CCR2 antagonist 3 (AZD-2927) is an antagonist of CCR2. | |||
TP1935L1 | RAGE antagonist peptide acetate | Beta Amyloid | |
RAGE antagonist peptide acetate is an advanced antagonist of glycation end products (RAGE). RAGE antagonist peptide acetate possesses anti-tumor and anti-inflammatory activities. RAGE antagonist peptide acetate prevents ... | |||
T12320 | ORL1 antagonist 1 | Opioid Receptor | |
ORL1 antagonist 1 is an o antagonist of pioid receptor-like 1 (ORL1) (IC50 of 61 nM). | |||
T10156 | CCR3 antagonist 1 | CCR | |
CCR3 antagonist 1 is a potent CCR3 antagonist, used for the research of inflammatory and immunologic diseases. | |||
T9983 | CCR8 antagonist 1 | LUN04765 | CCR |
CCR8 antagonist 1 is an antagonist of C-C Motif Chemokine Receptor 8 (CCR8) with a Ki value of 1.6 nM. | |||
T5829 | H4 Receptor antagonist 1 | Histamine Receptor | |
H4 Receptor antagonist 1 is a potent and selective histamine H4 receptor inverse agonist, with an IC50 of 19 nM. | |||
T10056 | Neurokinin antagonist 1 | Neuropeptide Y Receptor | |
Neurokinin antagonist 1 is a potent is a neuropeptide antagonist that can be used to study neurological disorders. | |||
T13453 | CGRP antagonist 1 | CGRP Receptor | |
CGRP antagonist 1 is a potent CGRP receptor antagonist with Ki values of 35 nM and IC50 values of 57 nM, respectively.CGRP antagonist 1 can be used for the study of cardiovascular and neurovascular diseases. | |||
T8848 | GPR34 receptor antagonist 2 | Tyrosine, N-[(2E)-3-(4'-chloro[1,1'-biphenyl]-4-yl)-1-oxo-2-propen-1-yl]-O-(phenylmethyl)-,gpr34-receptor-antagonist-2 | Others |
GPR34 receptor antagonist 2 (Tyrosine, N-[(2E)-3-(4'-chloro[1,1'-biphenyl]-4-yl)-1-oxo-2-propen-1-yl]-O-(phenylmethyl)-) is an anti-inflammatory agent. | |||
T10169 | 5-HT4 antagonist 1 | 5-HT Receptor | |
5-HT4 antagonist 1 is an antagonist of 5-HT4 (pKi = 9.6). |